Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Antibody-Drug Conjugate
Mabs
cancer therapy
cross-linking
drug targeting
payload
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Jul 2020
31 Jul 2020
Historique:
received:
14
07
2020
revised:
29
07
2020
accepted:
30
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
23
2
2021
Statut:
epublish
Résumé
In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a drug with cytotoxic activity cross-linked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor cells than on normal cells. By providing a selective targeting mechanism for cytotoxic drugs, ADCs improve the therapeutic index in clinical practice. In this review, the chemistry of ADC linker conjugation together with strategies adopted to improve antibody tolerability (by reducing antigenicity) are examined, with particular attention to ADCs approved by the regulatory agencies (the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)) for treating cancer patients. Recent developments in engineering Immunoglobulin (Ig) genes and antibody humanization have greatly reduced some of the problems of the first generation of ADCs, beset by problems, such as random coupling of the payload and immunogenicity of the antibody. ADC development and clinical use is a fast, evolving area, and will likely prove an important modality for the treatment of cancer in the near future.
Identifiants
pubmed: 32752132
pii: ijms21155510
doi: 10.3390/ijms21155510
pmc: PMC7432430
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Instruction, University, and Research
ID : National project PON ricerca e innovazione 2014-2020
Références
J Pharm Sci. 2020 Jan;109(1):74-103
pubmed: 31173761
J Cell Physiol. 2012 Mar;227(3):939-51
pubmed: 21503892
Transl Oncol. 2013 Dec 01;6(6):676-84
pubmed: 24466370
Eur J Med Chem. 2017 Dec 15;142:376-382
pubmed: 28818506
Cancer Res. 2006 Mar 15;66(6):3214-21
pubmed: 16540673
PLoS One. 2015 Jul 10;10(7):e0132282
pubmed: 26161543
Bioconjug Chem. 2002 Jul-Aug;13(4):855-69
pubmed: 12121142
Cancer Res. 2017 Dec 15;77(24):7027-7037
pubmed: 29046337
Acc Chem Res. 2008 Jan;41(1):98-107
pubmed: 17705444
J Cell Physiol. 2020 Jan;235(1):31-64
pubmed: 31215038
Clin Cancer Res. 2011 Oct 15;17(20):6417-27
pubmed: 22003069
Biomedicines. 2017 Nov 09;5(4):
pubmed: 29120405
Chem Soc Rev. 2019 Aug 12;48(16):4361-4374
pubmed: 31294429
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul 3;:e1653
pubmed: 32618433
J Control Release. 2018 May 10;277:48-56
pubmed: 29550398
J Cell Physiol. 2018 May;233(5):4091-4105
pubmed: 28941284
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16101-6
pubmed: 22988081
Cancer Res. 1992 Jan 1;52(1):127-31
pubmed: 1727373
J Med Chem. 2014 Aug 28;57(16):6949-64
pubmed: 24967516
J Med Chem. 1989 Mar;32(3):548-55
pubmed: 2783975
Oncogenesis. 2014 Aug 18;3:e117
pubmed: 25133484
Clin Cancer Res. 2015 Sep 1;21(17):3870-8
pubmed: 25944802
Adv Protein Chem Struct Biol. 2018;112:143-182
pubmed: 29680236
Pharmaceuticals (Basel). 2018 Apr 09;11(2):
pubmed: 29642542
Biochem J. 2006 Jun 1;396(2):235-42
pubmed: 16489930
Mol Pharm. 2019 Sep 3;16(9):3926-3937
pubmed: 31287952
Oncotarget. 2017 Sep 8;8(56):95412-95424
pubmed: 29221137
Toxins (Basel). 2016 Jul 25;8(8):
pubmed: 27463727
MAbs. 2012 Jan-Feb;4(1):17-23
pubmed: 22327427
Bioconjug Chem. 2017 Apr 19;28(4):1189-1193
pubmed: 28263569
Oncotarget. 2015 Jul 10;6(19):16902-11
pubmed: 26160848
Chem Sci. 2017 Jan 1;8(1):366-370
pubmed: 28451181
J Control Release. 2017 Oct 28;264:211-218
pubmed: 28867376
Ann Oncol. 2017 Dec 1;28(12):3083-3091
pubmed: 29045509
Nat Rev Cancer. 2006 Oct;6(10):764-75
pubmed: 16990854
Mol Cancer Ther. 2015 Nov;14(11):2606-12
pubmed: 26294742
Protein Eng Des Sel. 2010 Feb;23(2):61-8
pubmed: 19933699
Mol Cancer Res. 2020 Jan;18(1):3-19
pubmed: 31659006
Talanta. 2004 Oct 8;64(2):546-53
pubmed: 18969638
Org Biomol Chem. 2017 Jul 5;15(26):5635-5642
pubmed: 28649690
Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3796-827
pubmed: 24677743
MAbs. 2014 Jan-Feb;6(1):34-45
pubmed: 24423619
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841523
Talanta. 2020 Feb 1;208:120358
pubmed: 31816795
J Control Release. 2019 Jan 28;294:176-184
pubmed: 30553852
Pharm Res. 2015 Nov;32(11):3541-71
pubmed: 25986175
Nat Cell Biol. 2011 Dec 22;14(1):38-45
pubmed: 22193162
Protein Cell. 2018 Jan;9(1):33-46
pubmed: 27743348
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Nat Rev Drug Discov. 2010 Oct;9(10):790-803
pubmed: 20885410
Nat Biotechnol. 2015 Jul;33(7):733-5
pubmed: 26076429
SLAS Discov. 2020 Sep;25(8):843-868
pubmed: 32192384
Biomol Ther (Seoul). 2015 Nov;23(6):493-509
pubmed: 26535074
Bioconjug Chem. 2006 Jan-Feb;17(1):114-24
pubmed: 16417259
Acta Pharmacol Sin. 2015 Oct;36(10):1161-2
pubmed: 26388154
Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):101-8
pubmed: 25467949
Drugs. 2017 Sep;77(14):1603-1610
pubmed: 28819740
Microb Cell Fact. 2016 Nov 14;15(1):194
pubmed: 27842546
Drug Discov Today Technol. 2018 Dec;30:47-53
pubmed: 30553520
Bioorg Med Chem Lett. 1998 Dec 1;8(23):3347-52
pubmed: 9873732
Microb Cell Fact. 2015 Feb 13;14:19
pubmed: 25889802
Toxins (Basel). 2018 Feb 13;10(2):
pubmed: 29438358
Chem Rev. 2011 Apr 13;111(4):2815-64
pubmed: 21166464
Nat Rev Cancer. 2008 Jun;8(6):473-80
pubmed: 18469827
Drug Des Devel Ther. 2017 Aug 02;11:2265-2276
pubmed: 28814834
Pharmacol Ther. 2016 Nov;167:48-59
pubmed: 27492898
Cancer Immunol Immunother. 2006 Nov;55(11):1337-47
pubmed: 16485130
Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13817-21
pubmed: 25114240
Pharm Res. 2015 Nov;32(11):3526-40
pubmed: 25759187
Bioconjug Chem. 2014 Feb 19;25(2):351-61
pubmed: 24437342
Oncologist. 2018 Sep;23(9):1103-1108
pubmed: 29650683
Sci Rep. 2018 Aug 23;8(1):12652
pubmed: 30140073
Bioorg Med Chem Lett. 2016 May 1;26(9):2105-14
pubmed: 26988306
Curr Pharm Des. 2011;17(32):3527-47
pubmed: 22074425
Bioorg Med Chem Lett. 2019 Feb 1;29(3):466-470
pubmed: 30579797
Invest New Drugs. 2013 Apr;31(2):473-8
pubmed: 22965890
Oncoimmunology. 2017 Nov 20;7(3):e1395127
pubmed: 29375935
J Control Release. 2020 Apr 10;320:180-200
pubmed: 31978444
Int J Mol Sci. 2016 Apr 14;17(4):561
pubmed: 27089329
Trends Cell Biol. 2005 Jan;15(1):5-9
pubmed: 15653072
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19097-101
pubmed: 18025465
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1766-71
pubmed: 24443552
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448
pubmed: 30979742
Molecules. 2017 Aug 01;22(8):
pubmed: 28763044
Bioconjug Chem. 2015 Apr 15;26(4):650-9
pubmed: 25643134
Curr Pharm Des. 2020 Jul 01;:
pubmed: 32611300
Curr Drug Deliv. 2020 Jul 08;:
pubmed: 32640957
Methods Mol Biol. 2013;1045:51-70
pubmed: 23913141
Nat Biotechnol. 2003 Jul;21(7):778-84
pubmed: 12778055
Antibodies (Basel). 2020 Jan 08;9(1):
pubmed: 31936270
Mol Cancer Ther. 2018 Jul;17(7):1486-1493
pubmed: 29695631
J Cell Biochem. 2015 Jul;116(7):1256-66
pubmed: 25581839
Nature. 2003 Mar 6;422(6927):37-44
pubmed: 12621426
Adv Drug Deliv Rev. 2003 Feb 10;55(2):199-215
pubmed: 12564977
Drug Discov Today. 2017 Oct;22(10):1547-1556
pubmed: 28627385
Drugs. 2019 Sep;79(13):1467-1475
pubmed: 31352604
Cancer Res. 2009 Mar 15;69(6):2358-64
pubmed: 19258515
Cancer Chemother Pharmacol. 2000;46(4):263-71
pubmed: 11052623
Cancer Genomics Proteomics. 2011 Mar-Apr;8(2):49-63
pubmed: 21471515
BioDrugs. 2017 Dec;31(6):521-531
pubmed: 29119409
Mol Cancer Ther. 2013 Jun;12(6):968-78
pubmed: 23427296
Br J Cancer. 2017 Dec 5;117(12):1736-1742
pubmed: 29065110
Biotechnol Adv. 2015 Nov 1;33(6 Pt 1):775-84
pubmed: 25981886
Drug Discov Today Technol. 2018 Dec;30:63-69
pubmed: 30553522
Drugs. 2018 Nov;78(16):1763-1767
pubmed: 30357593
Clin Cancer Res. 2008 Oct 1;14(19):6171-80
pubmed: 18809969
Eur J Med Chem. 2014 Mar 3;74:302-13
pubmed: 24480360
Mol Cancer Ther. 2014 Nov;13(11):2618-29
pubmed: 25189543